Senate Finance Committee Chairman and Republican Chuck Grassley and the panel’s leading Democrat, Senator Ron Wyden, announced a bipartisan proposal to lower the Rx drug prices.
A federal appeals court panel expressed skepticism to Democratic calls to overturn the ruling of a Texas judge who found the landmark U.S. healthcare reform law unconstitutional.
Democratic presidential contenders battled over healthcare coverage and border policy during a surprisingly heated first debate that laid bare the party’s divisions on whether to abolish private insurance and shift to a Medicare-for-All system.
U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc. of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices – sometimes by more than 1,000 percent – and stifle competition for generic drugs, state prosecutors said.
U.S. Senator Bernie Sanders unveiled the latest version of his ambitious “Medicare-for-All” plan, moving the healthcare debate among Democratic presidential contenders to center stage in the 2020 race.
Democrats embraced U.S. President Donald Trump’s call to revive a fight over healthcare coverage, ensuring a prominent role for the issue in the 2020 election as Trump seeks a second term in office.
U.S. President Donald Trump is willing to work with congressional Democrats to lower drug prices for Americans and on infrastructure funding, White House adviser Kellyanne Conway said.
Republican pricing projects could hit industry bottom line
August 2018, Biosimilars, Congress, Consumers, Costs, Democrats, Department of Health and Human Services (HHS), Doctors, Donald Trump, FDA Commissioner, Generics, Issue Archives, Medicare, OTC, Pharmacies, Pricing, Republicans, Wall Street, White HousePrices, profits and promotional spend are closely linked. Reduce prices and promotion will plummet. But wait, the Republicans are in control. Accordingly, pharma, its marketing partners and even Wall Street often rest easy, especially when Republicans control Congress and the White House.
Health care continues to be one of the top issues that voters want to hear candidates talk about during their 2018 congressional campaigns, according to the results of Kaiser Health’s June 2018 tracking poll.
While many of us from blue states and urban bubbles fret over some of the actions of President Donald Trump, it’s good to take a clear-eyed view of whether or not Trump and this administration has been good for the medical marketing industries. Moreover, it’s useful to consider how a “blue wave” in the midterm elections might change the dynamic.